2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.21 Nimotuzumab Plus Chemotherapy in the Posterior Line Therapy of EGFR-TKIs Resistant Lung Adenocarcinoma: A Case Series Study

EP.12A.21 Nimotuzumab Plus Chemotherapy in the Posterior Line Therapy of EGFR-TKIs Resistant Lung Adenocarcinoma: A Case Series Study

Back to course

Pdf Summary

This document details a case series study exploring the efficacy and safety of nimotuzumab combined with chemotherapy for treating lung adenocarcinoma resistant to third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The study addresses the scarcity of effective treatments for patients with resistance to these inhibitors.<br /><br />The study involved 19 patients with metastatic, stage IV, EGFR-mutated lung adenocarcinoma resistant to third-generation EGFR-TKIs. Patients received nimotuzumab (600 mg every three weeks) alongside chemotherapy. The study followed-up for a median of 19.81 months. Key results showed nimotuzumab plus chemotherapy yielded favorable outcomes in overall survival (OS) and progression-free survival (PFS), with a 1-year OS rate of 68.02% and a 2-year rate of 61.83%. The median OS was not reached, and the median PFS was 4.30 months. The objective response rate (ORR) was noted at 26.3%, and the disease control rate (DCR) was 89.5%.<br /><br />Subgroup analysis suggested survival benefits among patients treated with nimotuzumab multiple times, and those with specific mutations. The safety profile indicated manageable side effects, with common severe adverse events including myelosuppression, nausea, and neutropenia, but no Grade 3-4 events directly attributed to nimotuzumab. No deaths related to treatment were observed.<br /><br />The study concludes that nimotuzumab combined with chemotherapy demonstrates encouraging efficacy and tolerable toxicity, advocating for further clinical trials of nimotuzumab as an alternative treatment for this patient group. The results support the consideration of nimotuzumab as a promising treatment option for patients with resistant lung adenocarcinoma, potentially improving survival outcomes in a demographic with limited alternatives.

Asset Subtitle

Kaihua Lu

Meta Tag

Speaker Kaihua Lu

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

nimotuzumab

chemotherapy

lung adenocarcinoma

EGFR-TKIs resistance

metastatic stage IV

overall survival

progression-free survival

objective response rate

disease control rate

safety profile